Medico Remedies working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
68.43×68.43×72.55×59.84×68.56×
123.07×123.07×129.15×107.96×93.81×
101.35×101.35×111.57×103.78×107.84×
90.15×90.15×90.13×64.02×54.53×
4.63×4.02×3.80×4.68×6.10×
1.51×1.51×1.40×1.58×1.61×
0.45×0.45×0.48×0.29×1.13×
0.34×0.34×0.33×0.19×0.85×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

MEDICO₹18.98

Medico Remedies Limited

· Pharma & Health
₹ CrorePeersMEDICAMEQHALEOSLABSAAREYDRUGSNECLIFEALBERTDAVDVALIANTLABNATCAPSUQZIMLABMcap ₹158 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)68.5659.8472.5568.4368.43
Receivable Days (DSO)93.81107.96129.15123.07123.07
Payable Days (DPO)107.84103.78111.57101.35101.35
Cash Conversion Cycle (days)54.5364.0290.1390.1590.15
Working Capital Turnover6.104.683.804.024.63
Asset Turnover1.611.581.401.511.51
Cash Conversion (CFO/Net Income)1.130.290.480.450.45
CFO/EBITDA0.850.190.330.340.34
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.